Table 2.
RTqPCR of predicted miR-96-5p mRNA targets identified in RNA sequencing in IIM patients versus controls
| Subgroup | RTqPCR | RNAseq | ||||
|---|---|---|---|---|---|---|
| Log2 fold change | T-test | Log2 fold change | FDR | |||
| Mean | ± | P-value | ||||
| ADK | PM | −0.64 | 0.87 | 0.0690 | −0.75 | 0.3520 |
| DM | −0.49 | 0.78 | 0.0960 | −0.56 | 0.8960 | |
| Anti-Jo1 | −0.82 | 0.63 | 0.0290 | −1.16 | 0.0337 | |
| CD28 | PM | −1.12 | 1.59 | 0.1240 | −0.91 | 0.2780 |
| DM | −0.63 | 1.01 | 0.2840 | −0.55 | 1.0000 | |
| Anti-Jo1 | −1.50 | 1.21 | 0.0340 | −1.34 | 0.0175 | |
| SLC4A10 | PM | −4.62 | 1.89 | 0.0010 | −5.12 | 0.0002 |
| DM | −4.02 | 1.25 | 0.0010 | −2.36 | 1.0000 | |
| Anti-Jo1 | −5.28 | 0.96 | 2.40E-05 | −8.86 | 8.36E-11 | |
PM Polymyositis, DM Dermatomyositis, Anti-Jo1 Subset of PM and DM with anti-Jo1 autoantibodies